S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens
    Meeting Abstract

    Einsele, H.; Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Scheid, C.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Alternative schedule of temozolomide/capecitabine (TEMCAP) administration in patients with neuroendocrine neoplasms
    Meeting Abstract

    Melhorn, P.; Mazal, P.; Wolff, L.; Popov, P.; Kretschmer-Chott, E.; Haug, A.; Mayerhoefer, M. E.; Raderer, M.; Kiesewetter, B.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Risk profiling of patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): 3-year update of the POLARIX study
    Meeting Abstract

    Oellerich, T.; Lenz, G.; Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Trnény, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Rieke, D. T.; Lin, J. I.; Tan, D. S.; Kummar, S.; Patel, J. D.; Cermignani, L.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Goetze, T.; Melisi, D.; Macarulla, T.; Cid, R. A. P.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Endoscopic and surgical management of non-metastatic ampullary neuroendocrine neoplasia: A multi-institutional pancreas 2000/EPC study
    Journal Article

    Karam, E.; Hollenbach, M.; Abou Ali, E.; Auriemma, F.; Anderloni, A.; Barbier, L.; Belfiori, G.; Caillol, F.; Crippa, S.; Del Chiaro, M.; more...
    Neuroendocrinology (2023)

    Fulltext@MSK | Save
  • The natural evolution of nevi with peripheral globules
    Journal Article

    Ilut, P. A.; Camela, E.; Lallas, K.; Papageorgiou, C.; Manoli, S. M.; Kyrgidis, A.; Liopyris, K.; Sgouros, D.; Apalla, Z.; Lallas, A.
    Dermatology (2023)

    Fulltext@MSK | Save
  • Durable response after olaparib treatment for perihilar cholangiocarcinoma with germline BRCA2 mutation
    Journal Article

    Costa, B. A.; Tallón de Lara, P.; Park, W.; Keane, F.; Harding, J. J.; Khalil, D. N.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save